On 11 August 2026, Mabwell announced that it has entered into licensing and commercialisation agreements with unidentified partners in the Philippines, Vietnam and Malaysia for 9MW0813, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) 2mg.
Under the terms of the agreements, Mabwell and its partners will work collaboratively to advance the product’s registration and commercialisation in each country. The announcement did not disclose the partners, financial terms or expected timeline for launch.
Mabwell’s biosimilar aflibercept was approved by China’s National Medical Products Administration (NMPA) in September 2025 for the treatment of diabetic macular oedema and neovascular (wet) age-related macular degeneration.
Mabwell has previously entered into licensing and commercialisation agreements for its denosumab biosimilars (Maiweijian™/9MW0321 and Mailishu™/9MW0311, biosimilars to Amgen’s Xgeva® and Prolia®) in the Philippines (July 2025 with UNILAB), Vietnam (March 2026 with undisclosed company) and Malaysia (April 2026 with undisclosed company). Under these agreements, Mabwell is responsible for the development, production and commercial supply of the products whilst the partner is responsible for registration, marketing and commercialisation.